Literature DB >> 18684702

Tigecycline pharmacokinetic/pharmacodynamic update.

Alasdair P MacGowan1.   

Abstract

This brief review summarizes recently published data on the pharmacokinetics and pharmacodynamics of tigecycline in man. Significant pharmacokinetic data are now available from the studies of infected patients, as is information on tissue distribution. Importantly, drug exposure-response relationships have been established for complicated skin and skin structure infections and intra-abdominal infection. These studies highlight the difficulties of undertaking pharmacodynamic studies in humans where account must be taken of both mixed pathogen infections and the potential impact of surgery. These data help to define the clinical role for tigecycline.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684702     DOI: 10.1093/jac/dkn242

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  26 in total

1.  In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.

Authors:  Teresa Spanu; Giulia De Angelis; Michela Cipriani; Barbara Pedruzzi; Tiziana D'Inzeo; Maria Adriana Cataldo; Gabriele Sganga; Evelina Tacconelli
Journal:  Antimicrob Agents Chemother       Date:  2012-05-29       Impact factor: 5.191

2.  Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis.

Authors:  Burke A Cunha
Journal:  J Clin Microbiol       Date:  2009-05       Impact factor: 5.948

3.  Multi-drug-resistant Klebsiella pneumoniae pancreatitis: a new challenge in a serious surgical infection.

Authors:  Derin Tugal; Melanie Lynch; Andrea M Hujer; Susan Rudin; Federico Perez; Robert A Bonomo
Journal:  Surg Infect (Larchmt)       Date:  2014-05-21       Impact factor: 2.150

4.  Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies.

Authors:  Michael J Satlin; Nina Cohen; Kevin C Ma; Zivile Gedrimaite; Rosemary Soave; Gülce Askin; Liang Chen; Barry N Kreiswirth; Thomas J Walsh; Susan K Seo
Journal:  J Infect       Date:  2016-07-09       Impact factor: 6.072

Review 5.  Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.

Authors:  Elizabeth A Neuner; Jason C Gallagher
Journal:  Virulence       Date:  2016-08-09       Impact factor: 5.882

6.  Tigecycline use in the outpatient parenteral antibiotic therapy setting.

Authors:  P R Ingram; M D M Rawlins; R J Murray; J A Roberts; L Manning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-20       Impact factor: 3.267

Review 7.  Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review.

Authors:  Vindana Chibabhai; Trusha Nana; Norma Bosman; Teena Thomas; Warren Lowman
Journal:  Infection       Date:  2017-09-15       Impact factor: 3.553

Review 8.  Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Thomas J Walsh
Journal:  Transpl Infect Dis       Date:  2017-10-25       Impact factor: 2.228

9.  The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies.

Authors:  Michael J Satlin; Stephen G Jenkins; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2014-01-23       Impact factor: 9.079

10.  Adjunctive Hyperbaric Oxygen Therapy or Alone Antibiotherapy? Methicillin Resistant Staphylococcus aureus Mediastinitis in a Rat Model.

Authors:  Tolga Kurt; Ahmet Vural; Ahmet Temiz; Ersan Ozbudak; Ali Umit Yener; Suzan Sacar; Mustafa Sacar
Journal:  Braz J Cardiovasc Surg       Date:  2015 Sep-Oct
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.